Accessibility Statement

Declaration of accessibility

Introduction

Legislative Decree No. 82 of May 27, 2022, transposes Directive (EU) 2019/882 of the European Parliament and the Council of April 17, 2019, on the accessibility requirements for products and services.

Guidelines on the accessibility of services, in implementation of Article 21 of Legislative Decree No. 82/2022 Version 1.0 dated 26 March 2024.

The decree was published in the Official Gazette (General Series No. 152 of 01-07-2022) and came into force on July 16, 2022, but its provisions will be effective from June 28, 2025.

U.G.A. Nutraceuticals Srl is committed to making its websites accessible in accordance with May 27, 2022, No. 82, which transposed Directive (EU) 2019/882 of the European Parliament and of the Council of April 17, 2019, on accessibility requirements for products and services. This accessibility statement applies to the websites https://www.omegor.com/

Description of the service

Status of compatibility with the requirements

The website https://www.omegor.com/ are partially compliant with the requirements of Annex A of UNI EN 301549:2018 (WCAG 2.1) due to the cases of non-compliance and/or exceptions listed below. U.G.A. Nutraceuticals Srl is conducting together with its suppliers an analysis aimed at making the necessary interventions to make the sites in question accessible and compliant with the standard.

Non-accessible content

The following content is not accessible because it is not compatible with the underlying harmonized standard EN 301 549:

  • On several pages there are images without captions. It is difficult to navigate to the images with screen readers.
  • There are links without link text on single pages.
  • On almost all pages, the contrast between text and background is too low.
  • There are invalid aria attribute values on several pages. These are not recognized by screen readers and are therefore not output correctly.
  • There are particularly important areas on a page that are marked with the role 'region' but have no labeling. This prevents screen reader users from recognizing the purpose and content of the area.
  • There are interactive elements on single pages whose names are not part of the caption. This makes it difficult to control the website using voice control.
  • There are elements on a page that are assigned to a role but do not contain the required attributes. These elements may not be displayed correctly by screen readers according to their role.

Some PDFs are not accessible, but we are actively working to replace our remaining PDFs with accessible versions. If you need a specific file immediately, please contact us.

The evolutions to the code made and future ones, have been and will be developed in compliance with WCAG 2.2 guidelines. The statement was drafted on 14/07/2026. The statement was made using an assessment in accordance with the requirements of Directive (EU) 2019/882 through self-assessment carried out directly by the provider. The declaration was created with the help of Eye-Able technology by Web Inclusion GmbH. More information about Web Inclusion GmbH can be found at https://eye-able.com/.
The declaration was last verified on 14/07/2026.

U.G.A. Nutraceuticals Srl is conducting an analysis with its suppliers to make the necessary changes to make the sites in question accessible and compliant with the regulations. U.G.A. Nutraceuticals Srl with a view to progressively improving the experience of its web customers, has also proactively implemented the SaaS Eye-Able software by Web Inclusion GmbH.

The functionality in question allows audits to scan individual pages of the site for digital barriers, providing compatible support that explains the error and proposes an alternative code to correct it, and other tools that allow website users to utilise important functions that can improve navigation. The company is committed to developing past and future code evolutions in accordance with WCAG 2.2 guidelines.

Feedback and contact details

Do you have a comment or remark about the barriers on this website? Please contact us. We will explain to you what barriers exist and how we want to improve our digital environments. We will answer your questions as soon as possible. Thank you for your feedback. For more information, please contact the following address:

U.G.A. Nutraceuticals S.r.l
Via Achille Varisco 2
20900 Monza
Tel.: +39 039 9000 200

In the email it will be necessary to indicate: Name and surname; Address of the web page or sections of the site or customer area subject to the report; Clear and concise description of the problem encountered; Tools used (operating system, browser, assistive technologies).

AGID

In the event of an unsatisfactory response or no response within thirty days to the notification or request, the data subject may send a report to the AGID:

AGID
Via Liszt 21
00144 Roma

Disclaimer

The automatic check of the web content was carried out on: 14/07/2026. For the web content accessed by Eye-Able, the Google Chrome browser in version 136.0.7103.92 was used. We guarantee the accuracy of the information provided for the tested application version under the specified browser and operating system parameters. If different versions or environments are used, a different display is possible, which may differ from the results given here. For a complete check, manual tests by the website operator are also recommended. In accordance with the AGID Guidelines on the accessibility of services, Version 1.0 of 04.03.2026, par. 5.1 "Obligations of the service provider", and in line with Opinion No. 33/2026 of the Data Protection Authority, it is specified that the service provided adopts appropriate measures aimed at preventing any form of tracking – whether through its own systems or those of third parties – of tools, solutions, and usage settings that could be associated with the ways in which users access digital content. The service does not carry out profiling activities nor does it use web tracking techniques (such as, by way of example, cookies other than technical cookies or fingerprinting techniques) capable of collecting information from which a user's disability condition could be inferred.